Major Tobacco Company Announces Acquisitions in Cannabis | CashCropToday
0 Shares 319 Views

Major Tobacco Company Announces Acquisitions in Cannabis

February 9, 2018
319 Views

Alliance One International (NYSE: AOI), a major tobacco company, announced this morning that the company has acquired 75% of Island Garden, a Canadian medical marijuana company, and 80% of Goldleaf Pharm., a nutritional pharmaceutical company. Alliance One International currently cultivates, processes, and manufactures tobacco products out of South Carolina, USA.

Island Garden is family owned business with a licensed medical marijuana operation, with 20,000 sq. ft. of an indoor grow. Though Goldleaf Pharma. does not currently own a cultivation license, the company has applied for one, and currently is constructing another 20,000 sq. ft. indoor grow cultivation facility. Goldleaf can also produce finished goods for the cannabis sector.

 

Constellation Brands, who owns the popular beer company Corona, paid Canopy Growth Corp (TSX: WEED), one of the largest cannabis producers in Canada, $190M for 10% stake in the company’s operations last October. Larger corporations are starting to see value in what is now expected to become a billion-dollar market in the next few years.

Link to the Press Release

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
271 views
Market Watch
271 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
194 views
Global
194 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
190 views
Manufacturing
190 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: